Get the weekly note

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

DYNF vs XBI: how they differ

DYNF and XBI hold 1% of their weight in the same names, and XBI returned more over the year.

iShares U.S. Equity Factor Rotation Active ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, DYNF and XBI hold 1% of their money in the same securities at the same weight.

Positions DYNF and XBI both hold, largest shared weight first
HoldingDYNFXBI
Gilead Sciences Inc0.42%0.97%
AbbVie Inc0.27%1.04%
Insmed Inc0.05%1.08%
Regeneron Pharmaceuticals Inc0.04%0.96%
Revolution Medicines Inc0.03%1.21%
Halozyme Therapeutics Inc0.03%1.03%
Ionis Pharmaceuticals Inc0.03%1.00%
Exelixis Inc0.02%0.96%
Largest positions each one holds and the other does not
Only in DYNFOnly in XBI
NVIDIA Corp 8.62%Apogee Therapeutics Inc 1.49%
Apple Inc 7.75%Moderna Inc 1.41%
Microsoft Corp 5.35%Twist Bioscience Corp 1.41%
Amazon.com Inc 4.42%Oruka Therapeutics Inc 1.38%
JPMorgan Chase & Co 3.59%Kymera Therapeutics Inc 1.36%
Broadcom Inc 3.25%Viking Therapeutics Inc 1.31%
Alphabet Inc 2.87%Praxis Precision Medicines Inc 1.29%
Cisco Systems Inc 2.76%Erasca Inc 1.27%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.

DYNF and XBI on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
DYNF
iShares U.S. Equity Factor Rotation Active ETF
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sitsCore index fundCore index fund
IssueriSharesState Street
What it isU.S. Equity Factor Rotation ActiveSPDR S&P Biotech
Total return, 1 year+20.8%+64.0%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500+3.3 pts+46.5 pts
Expense ratio0.26%0.35%
Already in the S&P 50098.8%8.5%
Holdings187150

DYNF in plain words

DYNF is an index equity fund tracking the U.S. Equity Factor Rotation Active. Over the year to Sep 11, 2026 it returned +20.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.26% a year. By its holdings filed for Apr 30, 2026, 99% of the fund by weight is stocks the S&P 500 also holds, across 187 positions, with the top ten at 43.8%.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, DYNF or XBI?
In the year to Sep 12, 2026, with distributions reinvested, DYNF returned +20.8% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, DYNF or XBI?
DYNF charges 0.26% a year and XBI charges 0.35%, so DYNF is cheaper. Fees come from each fund's prospectus.
How much do DYNF and XBI overlap with the S&P 500?
By their latest filed holdings, 99% of DYNF and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 1% of their books are the same securities at the same weight.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

DYNF against XBI, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, DYNF against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/DYNF-XBI Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources